BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28688124)

  • 1. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
    Chang PH; Yeh KY; Wang CH; Chen EY; Yang SW; Huang JS; Chou WC; Hsieh JC
    Head Neck; 2017 Oct; 39(10):1990-1996. PubMed ID: 28688124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
    Chang PH; Yeh KY; Wang CH; Chen EY; Yang SW; Chou WC; Hsieh JC
    Head Neck; 2017 Aug; 39(8):1573-1577. PubMed ID: 28449193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
    Chang CL; Yuan KS; Wu SY
    Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
    Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
    Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
    Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiotherapy in elderly patients with advanced head and neck cancer under intensive nutritional support.
    Chang PH; Yeh KY; Huang JS; Chen EY; Yang SW; Wang CH
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):228-35. PubMed ID: 25535674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
    Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
    Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic nutritional index relevance in chemoradiotherapy for advanced oral cavity, oropharyngeal and hypopharyngeal cancer.
    Chang PH; Hsieh JC; Yeh KY; Chen EY; Yang SW; Huang JS; Lai CH; Wu TH; Huang YM; Chang YS; Chou WC; Wang CH
    Asia Pac J Clin Nutr; 2018; 27(5):996-1001. PubMed ID: 30272847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
    Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
    Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral infarction after intraarterial and intravenous chemoradiotherapy for head and neck cancer: A retrospective analysis using a Japanese inpatient database.
    Suzuki S; Yasunaga H; Matsui H; Fushimi K; Saito Y; Yamasoba T
    Head Neck; 2016 Sep; 38(9):1354-8. PubMed ID: 27015638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
    Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
    Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment.
    Ghosh S; Rao PB; Kumar PR; Manam S
    Asian Pac J Cancer Prev; 2015; 16(16):7331-5. PubMed ID: 26514533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study.
    Ghosh S; Rao PB; Kumar PR; Manam S
    Asian Pac J Cancer Prev; 2015; 16(16):7309-13. PubMed ID: 26514529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
    Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
    Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
    David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
    Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
    Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
    J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.